The development of cancer is due to the growth and proliferation of transformed normal cells. Recent evidence suggests that the nature of oncogenic stress and the state of the cell of origin critically affect both tumorigenic activity and tumor histological type. However, this mechanistic relationship in mesenchymal tumors is currently largely unexplored. To clarify these issues, we established a mouse osteosarcoma (OS) model through overexpression of c-MYC in bone marrow stromal cells (BMSCs) derived from Ink4a/Arf (À/À) mice. Single-cell cloning revealed that c-MYC-expressing BMSCs are composed of two distinctly different clones: highly tumorigenic cells, similar to bipotent-committed osteochondral progenitor cells, and low-tumorigenic tripotent cells, similar to mesenchymal stem cells (MSCs). It is noteworthy that both bipotent and tripotent cells were capable of generating histologically similar, lethal OS, suggesting that both committed progenitor cells and MSCs can become OS cells of origin. Shifting mesenchymal differentiation by depleting PPARc in tripotent MSC-like cells and overexpressing PPARc in bipotent cells affected cell proliferation and tumorigenic activity. Our findings indicate that differentiation potential has a key role in OS tumorigenic activity, and that the suppression of adipogenic ability is a critical factor for the development of OS.
Introduction
Cancer is composed of a heterogeneous cell population that is generated through the transformation of normal cells into cancer cells. Identification of the cell type from which a given type of tumor arises (that is, the cell of origin) can form a basis for understanding the tumor biology and provide important clues for the development of diagnosis and therapy. Previous data on hematological malignancies have shown that not only multipotent stem cells, but also committed progenitor cells are susceptible to malignant transformation (Cozzio et al., 2003; Huntly et al., 2004; Krivtsov et al., 2006) .
As hematopoietic stem cells possess multi-lineage differentiation potential, they are considered to be candidate cells of origin for various types of hematological malignancies (Bonnet and Dick, 1997) . It is noteworthy that the observation that similar histological malignancies develop when multipotent hematopoietic stem cells and committed progenitor cells are exposed to the same oncogenic stressor (Cozzio et al., 2003) . Furthermore, there is evidence that the nature of oncogenic stress and the particular differentiation properties or state of the cell of origin may have critical roles in tumorigenic activity and tumor histological type (Huntly et al., 2004) . Although accumulated evidence has clarified the cancer cell of origin and mechanisms of transformation in hematological malignancies, such aspects of mesenchymal tumors are largely unknown. The use of genetic manipulation to establish mesenchymal tumors from normal mesenchymal cells in various differentiation stages might be expected to provide insight into these issues.
In this study, mouse bone marrow stromal cells (BMSCs) was used to discern which mesenchymal differentiation properties create conditions, which serve to favor or inhibit tumorigenesis. BMSCs, derived from mesenchymal stem cells (MSCs), comprise cells of various mesenchymal lineages at different stages of maturation (Gregory et al., 2005) . We have developed a mouse osteosarcoma (OS) model by overexpressing c-MYC in BMSCs derived from mice with a homozygous deletion of the Ink4a/Arf locus (Ink4aKO mice). Importantly, two distinct types of cells possessing different differentiation potentials are involved in the development of histologically similar lethal OS. The first of these cell types was found to be highly tumorigenic, and showed characteristics similar to those of osteochondrocyte-committed progenitor cells, whereas the second had low-tumorigenic potential and was similar to immature tripotent MSCs.
Further evaluation indicated that loss of adipogenic potential increases the potential for OS development. The modulation of adipogenic differentiation potential by depletion and overexpression of the adipogenic master regulator, PPARg, in tripotent MSC-like cells and bipotent cells, respectively, changed cell proliferation and tumorigenic activity.
Thus, these findings suggested that differentiation potential is a critical factor for regulating OS tumorigenic ability. Moreover, our in vitro-induced OS cells provide a powerful tool for basic and clinical research on OS.
Results

Establishment of Ink4aKO
BMSCs that overexpress c-MYC Mouse BMSCs were genetically manipulated to study the genetic alterations and differentiation properties required for transforming normal cells into tumorinitiating cells. We chose to focus on c-MYC that is overexpressed in various human tumors (Adhikary and Eilers, 2005) . We also used BMSCs isolated from the Ink4aKO mice in addition to those from wild-type (WT) mice, because recent reports suggest a close correlation between Ink4a inactivation and the maintenance of the tissue stem cell population (Janzen et al., 2006; Molofsky et al., 2006; Shibata et al., 2007) . Analysis of cell surface markers revealed that both WT and Ink4aKO BMSCs were positive for CD44, Sca-1 and Thy-1 (CD90.2), and were negative for CD45, CD31 and c-Kit (Figure 1a , data not shown). Under optimal differentiation conditions, both types of BMSCs were able to undergo adipogenesis, osteogenesis or chondrogenesis ( Figure 1b , data not shown), indicating that their differentiation potential was retained after isolation.
Next, c-MYC was introduced into these BMSCs by retroviral transfer, and we enriched infected cells positive for green fluorescent protein (GFP). Neither Adipogenic potential regulates tumorigenic activity in OS T Shimizu et al
Ink4aKO
BMSCs that were subjected to mock infection (Ink4a-GFP cells) nor WT cells overexpressing c-MYC (WT-MYC cells) manifested any differences in morphology relative to the parental cells in culture ( Figure 1c ). In contrast, Ink4aKO BMSCs that overexpressed c-MYC (Ink4a-MYC cells) were noticeably smaller ( Figure 1c ) and showed a marked growth advantage (Figure 1d ).
INK4a-MYC BMSCs form OS in syngeneic mice
To examine the tumorigenic potential of the genetically modified BMSCs in vivo, we injected the cells intraperitoneally into syngeneic C57BL/6 WT mice. All mice that received Ink4aKO (uninfected) or Ink4a-GFP BMSCs survived during the observation period of 420 days without apparent development of tumors ( Figure 2a ). In contrast, all of the mice injected with Ink4a-MYC BMSCs died within 60 days ( Figure 2a ). Post-mortem examination revealed widely disseminated tumors accompanied by highly invasive lesions. The tumors consisted of a fascicle of spindloid cells with widespread distribution of a homogeneous eosinophilic (osteoid) material (Figure 2b ). These histological features were reminiscent of OS. All tumor cells were GFP-positive and the nuclei of the tumor cells were strongly positive for c-MYC immunoreactivity. The formation of GFP-positive cartilage in the tumor lesions suggested that the injected cells contained chondrocytic progenitor cells. It is noteworthy that more than a year after the injection, two mice transplanted with WT-MYC BMSCs died from OS that were histologically similar to those derived from Ink4a-MYC BMSCs (Figure 2a ). These results indicate that overexpression of c-MYC in the context of Ink4a/Arf deletion induces transformation of BMSCs and confers on them the ability to form OS in vivo.
Recently, novel mouse OS models were developed through targeted deletion of p53 and Rb in osterixexpressing cells (Berman et al., 2008; Walkley et al., 2008) . INK4a/ARF exerts effects on both the Rb and p53 pathways (Collado et al., 2007) . Our experiments clearly showed that OS can be strongly triggered not only by the direct loss of Rb and p53, but also by the loss of INK4a/ARF. Previous studies of human tissue samples have indicated that loss of functional INK4a/ ARF has a critical role in the development of human OS (Benassi et al., 2001; Lopez-Guerrero et al., 2004) .
Although deregulation of c-MYC in human OS has been reported, the potential role of c-MYC in the pathogenesis of human OS is still unclear (Barrios et al., 1994; Gamberi et al., 1998) . To analyze the significance Adipogenic potential regulates tumorigenic activity in OS T Shimizu et al of c-MYC expression in human OS, we examined 23 OS specimens by gene expression profiling. In addition, nine normal human BMSCs were analyzed as putative cells of origin of OS and gastrointestinal stromal tumors (malignant mesenchymal tumors, examined as a control group), the etiology of which involves c-kit deregulation (Figure 2c ; Corless et al., 2004) . The levels of c-MYC expression in human OS samples varied and were significantly higher than in gastrointestinal stromal tumor specimens. However, although some OS specimens showed higher levels of c-MYC expression than BMSCs, we did not observe a significant overall difference in c-MYC expression between OS and normal BMSC samples (Figure 2c ). It should be noted that BMSCs show relatively high endogenous levels of c-MYC expression (Figure 2c, Supplementary Figure  1) . Collectively, these data suggest that c-MYC mRNA overexpression is not a general mechanism for the development of human OS. Therefore, our mouse model may not reflect all human OS cases with respect to pathogenesis.
Tumorigenic potential of osteochondrocyte-committed progenitor cells and immature multipotent cells
To identify OS cells of origin, we performed single-cell cloning of the Ink4a-MYC BMSCs. The obtained clones could be biologically divided into two groups on the basis of their differentiation potentials: one group, termed AO (adipo-osteo differentiation potential) cells, consisted of four clones with trilineage (adipogenic, osteogenic and chondrogenic) differentiation potential; the other group, termed AX (accelerated bone formation) cells, consisted of four clones with bilineage (osteogenic and chondrogenic) differentiation potential ( Figure 3a) . Given that all clones with adipogenic potential consistently showed osteogenic ability, we could not isolate cells possessing only adipogenic potential from Ink4a-MYC cells. Both AO and AX cells expressed high levels of c-MYC (Figure 3b ).
We next examined the tumorigenic potential of AO and AX cells by injecting them intraperitoneally into syngeneic mice. All mice injected with AX cells died from OS within 50 days (Figure 3c ). AO cells also generated lethal OS tumors, but at a lower frequency and with a far slower progression. There were no obvious histological differences in the OS formed by AO or AX cells (data not shown).
These results suggested that two distinct types of Ink4a-MYC cells, each with different differentiation properties, could both develop lethal OS.
Bipotent AX cells possess high-tumorigenic activity and differentiation capacity in vivo As the bipotent AX cells showed marked tumorigenic activity, we examined their characteristics in detail. All four AX cell clones possessed the same OS formation Adipogenic potential regulates tumorigenic activity in OS T Shimizu et al potential (data not shown). X-ray examination revealed extensive bone formation in mice injected with AX cells (Figure 4a ). Furthermore, subcutaneously injected AX cells showed marked metastatic potential, as observed in human OS (Figure 4b ). Inoculated AX cells generated mature bone and cartilage structures (Figure 4c ) through the activation of specific transcriptional genes. The nuclei of the tumor cells located in these mature bone and cartilage formations were strongly positive for Runx2 and Sox9 immunoreactivity, respectively. In contrast, nuclei from immature parts of the tumor were negative for these genes ( Figure 4d ). Moreover, immature tumor cells were enriched at the interface between normal tissue and OS, whereas osteogenesis and chondrogenesis were apparent mainly in the non-interfacial regions of the tumor (Figure 4c ).
We confirmed that these properties of AX cells could be retained through serial transplantation. We established an AX subline (termed AXT cells) in vitro from an AX-derived subcutaneous OS and then injected AXT cells intraperitoneally into syngeneic mice. All of the injected mice died within 20 days as a result of OS, the histological features of which were similar to AXderived tumors (Figure 4e , data not shown).
We then performed a limiting-dilution analysis to determine the number of AX cells required to form a lethal case of OS. Mice were injected with 10 000, 1000 or 100 cells, and over a period of 120 days, 100, 40 and 0%, respectively, died as a result of OS (Figure 4f) .
Together, these results suggest that bipotent AX cells possess high-tumorigenic activity as well as the capacity to differentiate, resulting in OS showing heterogeneous histology and a high propensity for distant metastasis in syngeneic mice.
AO and AX cells differ in their gene expression profiles
To gain insight into the origin of AO and AX cells, as well as to elucidate the molecular basis of the difference in tumorigenic potential between the two cell types, we compared their gene expression profiles. Of the 24 000 genes examined, we focused on those that contribute to differentiation or development (Table 1) . Key genes for the regulation of embryonic organogenesis (Hoxa5, Hoxa9, Foxc1 and Foxf2) and the commitment of immature cells to multiple lineages (Pparg, Cebpa, Plxnd1, Egfl7, Mgp, Plxdc2, Ebf1 and Tcf3) were expressed at higher levels in AO cells than in AX cells, suggesting that AO cells have characteristics of immature mesenchymal cells (Wang and Reed, 1993; Luo et al., 1997; Wu et al., 1999; Rosen et al., 2000; Parker et al., 2004; Torres-Vazquez et al., 2004; Miller et al., 2007; Cole et al., 2008) . The profile of AX cells, on the other hand, was indicative of both cells that are committed to the osteocyte lineage (Dlx3, Sp7, Dkk1, Ostn and Bmp3) and cells that are inclined to tumorigenesis in vivo (Cd276, Ptgs2, Vegfa, Epha2, Frzb and Sfrp1) (Kim et al., 1993; Daluiski et al., 2001; Dannenberg et al., 2001; Thomas et al., 2003; Lee et al., 2004 Zang et al., 2007; Brantley-Sieders et al., 2008; Engin et al., 2008; Li et al., 2008) .
We examined the expression of adipogenic or osteogenic genes in AO and AX cells. The expression levels for adipogenic genes, including Pparg, Lpl and Fabp4, became elevated in Ink4aKO and AO cells under adipogenic culture condition (Figure 5a ). In contrast, the expression of these three genes was never detected in AX cells, even under adipogenic conditions. In contrast, among several osteogenesis-related genes, the expression of Sp7 was higher in AX cells than in AO cells (Figure 5b) . Runx2, Bglap, Ibsp and Alp were expressed equally in AO and AX cells (Figure 5b and data not shown), although their expression levels in both cell types were higher than in parental Ink4aKO cells. These findings also support the notion that AO cells originate from MSCs, but AX cells originate from more differentiated, osteochondrocyte-committed progenitor cells.
Suppression of adipogenic ability in OS
These findings indicated that lineage-committed cells (AX) were more tumorigenic than immature MSC-like cells (AO). Thus, we hypothesized that the adipogenic potential lost in AX cells might affect tumorigenic activity in AO cells in vivo. We examined the alteration of adipogenic ability in tripotent AO cells through OS development. We established sublines from AO-derived late-onset OS tumor cells (termed AOT). It is noteworthy that the adipogenic potential was markedly reduced in AOT cells compared with that of parental AO cells (Figure 5c ). Adipogenic conditions scarcely induced the expression of Pparg in AOT cells, in contrast to the expression profile of parental AO cells ( Figure 5d ).
Next, we focused on the adipogenic process in human OS. The activation of PPARg expression is a marker of adipogenesis (Rosen et al., 2000, Figure 5a ). Under adipogenic conditions, PPARG expression was markedly elevated in normal human BMSCs undergoing adipogenesis (Figure 5e and f) . In contrast, these adipogenic changes were not observed in SAOS2 or SJSA1 cells, a similar result to that observed in bipotent AX cells.
To further analyze adipogenic potential in human OS, we examined PPARg expression in human OS. Fluorescence immunohistochemistry revealed that PPARg expression is rarely detected in the cellular nuclei of human OS specimens (1.41±0.35%) (n ¼ 3), whereas it has been detected in most nuclei from liposarcoma samples (n ¼ 2) (positive controls) (Figure 5g ). Furthermore, gene expression profiling of human tumor specimens revealed that PPARG expression was lower in the OS specimens (n ¼ 23) than in normal human BMSCs (n ¼ 9) under steady state (non-adipogenic) conditions (Figure 5h) .
Collectively, these results suggested that cellular signals related to adipogenesis are suppressed in human OS. We therefore speculated that OS can develop in both osteo-committed progenitors and MSCs in which the adipogenic process has stalled.
Loss of adipogenic potential because of PPARg downregulation affords a growth advantage to tripotent AO cells and enhances osteogenesis These findings raise the intriguing possibility that osteochondrocyte-lineage commitment enhances tumorigenic activity during the development of OS from multipotent MSCs. Therefore, we modified the differentiation properties of tripotent AO cells by depletion of PPARg using a short hairpin RNA. Introduction of the PPARg-specific short hairpin RNA into AO cells (Figure 6a ). The knockdown of PPARg had no effect on cell proliferation under normal growth conditions (data not shown), however, under adipogenic conditions, AO and AO-shLuc cells underwent almost complete growth arrest after 4 days in culture, whereas AO-sh4 and AX cells continued to proliferate (Figure 6b ). Nuclear Ki67 was also more abundant in AO-sh4 and AX cells after 3 days of adipogenic conditions than in AO or AO-shLuc cells (Figure 6c ). Under osteogenic conditions, intracellular calcium deposition was enhanced in AO-sh4 cells compared with parental AO cells or AO-shLuc cells (Figure 6d ). Sp7 and Runx2 expression under normal growth conditions was increased through PPARg downregulation (Figure 6d ), suggesting that AO-sh4 cells were similar to osteocyte-committed progenitors. These findings were compatible with recent reports that the differentiation of MSCs into adipocytes or osteocytes was mutually exclusive and was regulated at the transcriptional level (Rosen et al., 2000; Hong et al., 2005) . AO cells depleted of PPARg thus appeared to have escaped terminal adipogenic differentiation and its accompanying cell cycle arrest, mimicking lineage-committed AX cells in their proliferation and differentiation properties in vitro.
Adipogenic potential restored by PPARg expression suppresses tumorigenic activity of AX cells in vivo To further clarify the influence of adipogenic potential on OS tumorigenesis, AX cells that overexpress mouse PPARg were generated. It is noteworthy that overexpression of PPARg in AX cells restored their ability to differentiate into adipocytes, as if AX cells were 'reprogrammed' to more immature cells. We performed single-cell cloning and isolated sublines of AX cells The Cy5 (AO cells)/Cy3 (AX cells) ratio for each gene was calculated after subtraction of the background signal and after global median normalization. The normalized data were analyzed to identify genes whose expression appeared to differ between the two cell types by a factor of X2.
Adipogenic potential regulates tumorigenic activity in OS T Shimizu et al (AXPP cells) with different expression levels of Pparg (Figure 7a ) and different adipogenic potential (Figure 7b ). Whereas AXPP1, -5 and -7 cells possessed low adipogenic potential, scarcely forming lipid droplets under adipogenic conditions, both AXPP6 and AXPP11 cells expressed higher levels of PPARg and showed high adipogenic potential. Osteogenic potential was retained in all AXPP clones (Figure 7b) . Syngeneic mice were then injected with AXPP cells. Although all AXPP sublines eventually formed lethal OS, AXPP6 and AXPP11 cells generated tumors with a longer latency than AXPP1, -5 and -7 cells (Figure 7c ). All mice inoculated with clones without adipogenic potential died within 30 days after injection, whereas for mice injected with the adipogenesis-restored clones AXPP6 and AXPP11, survival ratios at 30 days were 80 and 40%, respectively. It should be noted that although AXPP11 is the highest Pparg-expressing clone, it did not produce tumors associated with the longest survival. This might be a consequence of the differential susceptibility to downregulation of forced PPARg expression in the clones in vivo. Related to these findings, analysis of newly established OS cells from adipogenesis-restored clones (AXPPT 6 and 11 sublines) revealed that their adipogenic ability and forced PPARg expression was consistently lost during the development of OS (Figures 7d and e) , which mimicked the alteration of tripotent AO cells into highly tumorigenic AOT cells in vivo (Figure 5c ).
These results again indicate that the restoration of adipogenic potential by introduction of PPARg attenuates tumor-initiating activity, and that suppression of adipogenic potential seems to be a key event for the initiation of OS.
Discussion
The OS-initiating cells developed in this study possess the following unique characteristics: (1) they were derived from BMSCs that carried two genetic changes, overexpression of c-MYC and loss of Ink4a/Arf; (2) they formed lethal metastatic OS in immunocompetent syngeneic mice over a short period of time; (3) they could be maintained in an immature state in vitro, and differentiate into bone and cartilage in vivo during tumorigenesis. One of the most interesting results of this study was that histologically similar lethal OS developed from two distinct types of cells with different differentiation potential (that is, tripotent or bipotent) with very different frequencies and duration (Figure 3c ). These results indicate that adipogenic potential is a key factor in the regulation of OS tumorigenesis. Whether OSinitiating cells possess adipogenic potential remains an open question (Haydon et al., 2002; Li et al., 2009) . In fact, human U2OS cells, which were established from an osteogenic tumor (Ponten and Saksela, 1967) , but showed adipogenic capability (Supplementary Figure  2) , were generally non-tumorigenic in vivo (Dass et al., 2006) . Although tumorigenic ability may depend on the transforming oncogene and/or species of origin, we observed that OS cells were irreconcilable with adipogenic ability during tumorigenesis (Supplementary Figure 3) . First, tripotent AO cells, which are presumably of MSC origin (Figure 3a and Table 1 ), lost their adipogenic potential on OS development and transformed into AX-like cells in vivo (Figure 5c and data not shown). Second, adipogenic potential attenuated the tumorigenic activity of bipotent AX cells (Figure 7c) . The eventual activation of PPARg in vivo might drive tripotent cells to terminal differentiation into adipocytes, a process that is accompanied by cell cycle arrest (Figures 6b and c) or it might simply correlate with cell cycle arrest and apoptosis in vivo, as reported for several other tumor types (Koeffler, 2003) . We speculate that suppression of PPARg expression is critical for OS development, an idea supported by its complete loss during OS initiation in our model.
Recent reports describing novel OS models indicate that OS originates from lineage-committed immature osteoblasts or MSCs (Berman et al., 2008; Walkley et al., 2008) . Our model suggested that OS can originate from both types of cells. There is no category describing such histological findings as the mixture of bone formation and adipogenesis in human OS classification (Fletcher et al., 2002) . In fact, differentiation of normal MSCs into adipocytes or osteocytes is thought to be mutually exclusive and is regulated at the transcriptional level (Rosen et al., 2000; Hong et al., 2005) . In addition, PPARg expression was suppressed in human OS specimens (Figures 5g and h ). These results suggest that osteo-committed progenitors or tripotent immature BMSCs in which the adipogenic process has stalled are the likely candidates for cells of origin of OS.
Deletion of Ink4a/Arf and overexpression of c-MYC in BMSCs did not result in the development of other types of mesenchymal tumors. Other oncogenic stresses, such as expression of the FUS-CHOP fusion gene, have been shown to induce transformation of multipotent BMSCs, leading to the development of liposarcoma (Riggi et al., 2006) . Therefore, the combination of a specific type of oncogenic stress with a naturally susceptible cell of origin might have a critical role in the determination of mesenchymal tumor histological type.
Whether AX-derived tumors adhere to the cancer stem cell (CSC) model remains to be determined. Like other stem cells, CSCs self-renew and generate heterogeneous cancer cell lineages (Reya et al., 2001; Pardal et al., 2003) . In this study, inoculated AX cells generated structures with heterogeneous differentiation patterns in vivo (Figure 4c ). In addition, AX cells efficiently initiated secondary tumors that recapitulated the organization of the primary tumor (Figure 4e ). These findings raise the possibility that AX-derived tumors contain OS CSCs. However, in this study, we did not distinguish phenotypically distinct populations of tumorigenic cells that could self-renew (that is, CSCs) from less-or non-tumorigenic sub-populations (nonCSCs). Although immature cells at the periphery of the tumor (Figure 4c ) may represent candidates for such a CSC-like population, we cannot rule out the possibility that differentiated cells show plasticity and can revert to immature cells to initiate tumor growth. Further investigation is needed to determine whether AX cells contain a CSC population.
Our in vitro-developed OS cells show properties of differentiation and metastasis in syngeneic mice that mimic human disease. We present this model as a potentially powerful tool for basic and clinical research on OS.
Materials and methods
Cell culture
BMSCs were isolated from 10-week-old male WT C57BL/6J and Ink4aKO C57BL/6 (B6.129-Cdkn2atm1Rdp; NCI Frederick, Frederick, MD, USA) mice. Bone marrow cells were obtained by flushing femurs and tibias with phosphatebuffered saline, and then hematopoietic cells were depleted by autoMACS (Miltenyi Biotec, Bergisch Gladbach, Germany) with biotin-conjugated antibodies to mouse CD45 (eBioscience, San Diego, CA, USA) and biotin-conjugated antibodies to lineage-specific antigens (Miltenyi Biotec). BMSCs were cultured in Iscove's modification of Dulbecco's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 20% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml). They were used for experiments within eight passages. Human OS cell lines (U2OS, SAOS2 and SJSA1) Adipogenic potential regulates tumorigenic activity in OS T Shimizu et al were purchased from ATCC (Manassas, VA, USA) and cultured with Iscove's modification of Dulbecco's medium supplemented with 10% fetal bovine serum. Normal healthy human BMSCs were purchased from Lonza (Basel, Switzerland).
Plasmid and retroviral gene transfer Human c-MYC (kindly provided by M Miwa) and mouse Pparg2 complementary DNA (ImaGenes, Berlin, Germany) was cloned into the retroviral plasmids pMXs-Ig and pMXspuro (both kindly provided by T Kitamura), respectively. Retroviral gene transfer was performed as previously described (Kitamura et al., 2003) . Infected cells were sorted by FACSVantage SE (BD, Franklin Lakes, NJ, USA), or were subjected to selection in the presence of 3 mg/ml puromycin.
Differentiation assays
For induction of adipogenesis or osteogenesis, cells were incubated in 20% fetal bovine serum containing Iscove's modification of Dulbecco's medium supplemented with appropriate materials, as described elsewhere (Peister et al., 2004) . Chondrogenesis induction was performed as previously described (Peister et al., 2004) .
Flow cytometry
Single-cell suspensions were prepared in phosphate-buffered saline and then incubated with phycoerythrin-conjugated antibodies to CD45, CD90.2, CD31, Sca1, c-Kit, CD44, or CD133 (eBioscience). The labeled cells were analyzed with FACSCalibur (BD) and Cell Quest software (BD). At least 10 000 live cells were examined.
Cell proliferation assay
Cells were transferred to 96-well tissue culture plates and cultured under adipogenic condition. Cell proliferation was measured with the use of an XTT cell proliferation assay kit (Roche Diagnostics, Mannheim, Germany). All assays were performed in triplicate.
Immunoblot analysis
Immunoblot analyses were performed according to standard procedures with primary antibodies to c-Myc (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a-tubulin (Sigma-Aldrich, St Louis, MO, USA).
Tumor xenograft model
All animal care and procedures were performed in accordance with the guidelines of Keio University. For xenograft experiments, cells were suspended in phosphate-buffered saline and then injected intraperitoneally or subcutaneously into syngeneic 8-week-old female C57BL/6 mice.
Reverse transcriptase (RT)-PCR/real-time RT-PCR analysis
Total RNA was extracted with RNeasy Mini Spin columns (Qiagen, Hilden, Germany) and was subjected to RT using the Prime Script RT-PCR kit (Takara, Shiga, Japan). Real-time RT-PCR analysis was performed using SYBR Premix Ex TaqII and Thermal Cycler Dice (Takara). Data are represented as means±s.d. from three independent experiments. The sequences of the primers used in this study are shown in Supplementary Table S1 .
Human samples
For the experimental use of OS and gastrointestinal stromal tumor surgical samples, informed consent was obtained from the patients in accordance with the Hospital Ethical Guidelines of Keio University Hospital and the National Cancer Center Hospital.
Immunohistochemistry
Immunohistochemical analysis was performed using standard methods. Deparaffinized sections were stained with rabbit polyclonal antibodies to GFP, c-Myc, Sox9 (Santa Cruz Biotechnology) or Runx2 (Novus Biologicals, Littleton, CO, USA). For immunocytochemistry, cells were fixed with acetone and stained with rat monoclonal antibodies to Ki67 (Dako, Glostrup, Denmark). Immune complexes were detected with the use of Histofine (Nichirei Bioscience, Tokyo, Japan) and Simple Stain Kit (Nichirei Bioscience). For immunofluorescence staining, deparaffinized sections were stained with anti-PPARg (Santa Cruz Biotechnology) followed by Alexa488-conjugated anti-mouse IgG secondary antibodies (Invitrogen). TOTO3 (Invitrogen) was used for nuclear staining.
Gene expression profiling
Comparison of AO and AX cells was performed using the 3D-DNA chip (Toray, Tokyo, Japan) according to the manufacturer's instructions. The normalized data were used to identify genes whose expression appeared to be upregulated or downregulated by a factor of X2. The intensity values were log10-and Z-transformed, and then subjected to cluster analysis using Cluster v2.1.1 software (Eisen et al., 1998) . Genes with Z-transformed values that differed by more than one point were extracted.
For analysis of human specimens, total RNA was analyzed with a GeneChip Human Genome U133 plus 2.0 array, as recommended by the manufacturer (Affymetrix, Santa Clara, CA, USA). The expression value (signal) for each probe set (MYC (202431_s_at), PPARG (208510_s_at) and ACTB (200801_x_at)) was calculated with the use of GeneChip Operating Software version 1.3 (Affymetrix).
RNA interference
For the introduction of short hairpin RNAs into cells, the retroviral expression vector pRePS (kindly provided by T Hara) was used, which also contains the puromycin resistance gene. The sequences of the sense oligonucleotides were 5 0 -GTT TGAGTTTGCTGTGAAG-3 0 for PPARg short hairpin RNA-4 and 5 0 -CGTACGCGGAATACTTCGA-3 0 for luciferase (nonspecific control). AO cells were infected with retroviral vectors as previously described (Fujino et al., 2006) , and were then subjected to selection in the presence of puromycin (3 mg/ml).
